NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Real World Study in Locally Advanced or Metastatic NSCLC Patients, Progressed From First-line EGFR-TKI Therapy

NCT04207775

CompletedN/A

Sponsor: AstraZeneca

Conditions: Locally Advanced or Metastatic NSCLC

Countries: China

To estimate parameters associated with treatment patterns and related clinical outcomes.Including physician reported PFS and OS.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria

1. Male or female patients with age ≥18 years old
2. Histologically or cytologically confirmed locally advanced or metastatic NSCLC patients
3. Patients with prior confirmed EGFR mutation-positive, who have progressed from first line EGFR-TKI\*
4. Provision of written informed consent by the patient should be within 6 weeks of the date of progression from first line EGFR-TKI treatment \*Note：

   1. First-line EGFR-TKI is monotherapy;
   2. EGFR-TKI has been launched in China includes first-generation, second-generation or third-generation EGFR-TKI, but not including the original chemical compound
   3. Exclude the Chinese traditional medicine that is being used to treat lung cancer
   4. Progression was determined according to Recist1.1 criteria.

Exclusion Criteria

1. Involvement in the planning and/or conduct of the other intervention study
2. Previous enrolment in the present study
3. Pregnancy or breast-feeding

Locations (16)

Beijing, China
Changsha, China
Chengdu, China
Chengdu, China
Guangzhou, China
Guangzhou, China
Hangzhou, China
Harbin, China
Hohhot, China
Qingdao, China
Shenyang, China
Suzhou, China
Taizhou, China
Xi'an, China
Xi'an, China
Zhuji, China